PFKFB4 and hepatocellular carcinoma: Furthermore, PFKFB4 functions as a pivotal regulator in both lenvatinib resistance and HCC progression, highlighting its promise as a potential therapeutic target to overcome drug resistance and improve clinical outcomes in HCC patients.